Psyence Biomedical Ltd. (PBM) stock
PBMNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBMWW
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jun 22, 2026Score 0/30
$4.12−0.10 (-2.37%)
Close on Oct 19, 2026Market cap –P/E –Yield –
Psyence Biomedical r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was $1.47M, up 328.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $1.47M | +328.6% |
| FY2025 | Mar 31, 2025 | $342.17K | -64.2% |
| FY2024 | Mar 31, 2024 | $954.59K | -40.7% |
| FY2023 | Mar 31, 2023 | $1.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $357.44K | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $265.63K | – |
See a number that looks wrong?